Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: Once symptoms appear, rabies is almost always fatal and accounts for 200-300 deaths annually in the Philippines. Available rabies vaccines can be administered either in pre- exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP). After exposure, PrEP-immunized individuals require fewer doses of PEP and no rabies immunoglobulin.

Methods: A static decision-tree model was developed to assess cost-effectiveness of a PrEP+PEP program vs PEP alone. Philippines-specific data for people seeking medical advice at the Research Institute for Tropical Medicine between July 2015 and June 2016 were used in the model, together with data from published literature.

Results: Over a 20-year period, in a cohort of 1 million 5-year-old children in the Philippines, PrEP+PEP was expected to prevent 297 deaths compared with PEP alone. From both payer and societal perspectives, the resulting incremental cost-effectiveness ratios were 36 035 (US$759; 2016 US$ conversion) and 18 663 (US$393) Philippine Pesos (PHP) - quality-adjusted life-years gained - respectively, which are both below the willingness-to-pay threshold of PHP140 255 (US$2 953).

Conclusion: These data suggest that a universal PrEP program targeting 5-year-olds would be cost-effective in the Philippines.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijid.2020.05.062DOI Listing

Publication Analysis

Top Keywords

post-exposure prophylaxis
8
health economic
4
economic assessment
4
rabies
4
assessment rabies
4
rabies pre-exposure
4
prophylaxis
4
pre-exposure prophylaxis
4
prophylaxis program
4
program compared
4

Similar Publications

Transgender women and sex workers in Brazil underutilise HIV prevention services. Understanding preferences and decision-making regarding HIV prevention can help develop new programmes to meet their needs. We conducted semi-structured interviews with 26 transgender women and travesti sex workers in São Paulo, Brazil.

View Article and Find Full Text PDF

Doxycycline Post-Exposure Prophylaxis Update at CDPH STI Specialty Clinics, 2024.

Sex Transm Dis

September 2025

Chicago Department of Public Health, Syndemic Infectious Disease Bureau, 1340 S. Damen Ave., 4th Floor, Chicago, IL 60608.

View Article and Find Full Text PDF

Human immunodeficiency viruses (HIV) and, subsequently, acquired immune deficiency syndrome emphasize the significance of prevention and treatment, especially among vulnerable populations. Some subgroups of the LGBTQIA+ community, namely men who have sex with men (MSM) and transgender individuals, can be disproportionately affected by this disease. As the health care community recognizes this health concern, post-exposure prophylaxis has become important in preventing HIV spread.

View Article and Find Full Text PDF

Nondisclosure of use of antiretroviral medications in Canadian blood donors.

Transfusion

September 2025

Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.

Introduction: Donors are deferred if they are on antiretroviral medications (ARV) as post-exposure or pre-exposure prophylaxis (PEP or PrEP) for human immunodeficiency virus (HIV). We assessed donor compliance by measuring ARV levels in selected anonymized donor samples collected from September 22, 2022 to December 31, 2024, almost all after the introduction of sexual risk behavior screening.

Methods: EDTA plasma samples collected at the time of donation (retention samples) were retrieved, frozen, and shipped for measurement of tenofovir and emtricitabine.

View Article and Find Full Text PDF

An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques.

Cell Rep

September 2025

National Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; State Key Laboratory of Respiratory Health and Multimorbidity, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; Center for

LP-98 is a lipopeptide HIV fusion inhibitor showing strong treatment and pre-exposure prophylaxis efficacies in non-human primates. In this study, we further characterized its pharmacokinetics, long-lasting antiviral activity, and post-exposure prophylaxis (PEP) efficacy using 62 macaques. In cynomolgus macaques, LP-98 achieved high concentrations (C) with a half-life (T) of ∼31 h, and sustained an effective therapeutic concentration for two weeks post-injection.

View Article and Find Full Text PDF